Business Wire15d
Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and ...
Emcure Pharmaceuticals partners with Gilead Sciences to produce HIV prevention drug Lenacapavir
Emcure Pharmaceuticals on Thursday announced a royalty-free voluntary licensing agreement with Gilead Sciences Ireland UC, a ...
Gilead, LEO Pharma partner to develop programs for inflammatory diseases
Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat ...
Reuters12d
Gilead Sciences, US government settle patent case over HIV prevention drugs
Jan 15 (Reuters) - Gilead Sciences (GILD.O), opens new tab and the U.S. government have settled a billion-dollar patent ...
pharmaphorum1d
NICE recommends first CAR-T cell therapy on NHS in England
Dr Véronique Walsh, VP and GM at Gilead Sciences UK & Ireland, commented: “This news comes at a time when new hospitals are preparing to deliver CAR-T cell therapies and will mean that ...
Hosted on MSN3mon
Dr Reddy's, Hetero ink royalty-free voluntary licencing pacts with Gilead Sciences for HIV drug Lenacapavir
royalty-free voluntary licencing agreements with Gilead Sciences Ireland UC to manufacture and distribute the latter's human immunodeficiency virus (HIV) drug Lenacapavir in India and 120 low- and ...
Gilead Sciences: Strategic Growth and Optimism Amidst Market Challenges
Jefferies analyst Michael Yee maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...
Gilead Sciences: Supreme Court Case and New Innovations Drive Buy Rating
Michael Yee, an analyst from Jefferies, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price target ...